Chinook Therapeutics, Inc.
https://www.chinooktx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chinook Therapeutics, Inc.
Finance Watch: Fresh Cash For Life Science Firms From venBio, Symbiotic
Private Company Edition: Symbiotic Capital emerged with a $600m-plus fund to provide credit for private and public companies, while venBio raised a $528m fund. Also, Outpace Bio raised $144m, Jade Biosciences launched with $80m and MBX Biosciences raised $63.5m.
Novartis Aims To Dominate Rare Renal Disorders
Fabhalta and atrasentan are odds-on for approval in C3 glomerulopathy and IgA nephropathy, respectively, but commercial success might be harder to come by.
Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal
Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab.
Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence
The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Aduro Biotech, Inc., BioNovion BV, Aduro Biotech Europe
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice